Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 4/20 | 0.57 |
| ▸ | DRD2 | P14416 | 3/20 | 0.57 |
| ▸ | HTR1A | P08908 | 2/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.56 |
| ▸ | HTR7 | P34969 | 2/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | DRD1 | P21728 | 1/20 | 0.55 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6781864 | 0.88 | DRD2 (0.58) | DRD3DRD2HTR1AHTR2AHTR2C | |
| SCHEMBL6785423 | 0.87 | DRD2 (0.51) | DRD3DRD2HTR1AHTR2AHTR7 | |
| Hydrochloric Acid SCHEMBL6793607 | 0.87 | DRD2 (0.57) | DRD3DRD2HTR1AHTR2AHTR7 | |
| SCHEMBL30041328 | 0.84 | HRH4 (0.69) | DRD3DRD2HTR1AHRH4DRD4 | |
| SCHEMBL8682915 | 0.84 | HRH4 (0.69) | DRD3DRD2HTR1AHRH4DRD4 | |
| SCHEMBL5419290 | 0.80 | CHRNA7 (0.57) | DRD3DRD2HTR2CHRH4DRD1 | |
| SCHEMBL6864697 | 0.77 | SIGMAR1 (0.76) | DRD3DRD2HTR1AHTR7SIGMAR1 | |
| SCHEMBL23964200 | 0.77 | HRH4 (0.63) | DRD3DRD2HTR1AHRH4ADRA2A | |
| SCHEMBL9393661 | 0.77 | DRD4 (0.67) | DRD3DRD2HRH4KDM4EDRD4 | |
| SCHEMBL30041451 | 0.77 | HRH4 (0.63) | DRD3DRD2HTR1AHRH4ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040198734-A1 | 2-(4-Aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives interacting with the dopamine | PFIZER INC | 2004-10-07 | — | — | US | claimed |
| US-20040116443-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC | 2004-06-17 | — | — | US | claimed |
| US-20030158208-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC. | 2003-08-21 | — | — | US | claimed |
| US-20030100757-A1 | 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives interacting with the dopamine D4 receptor | PFIZER INC. | 2003-05-29 | — | — | US | claimed |
| US-20020049209-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC. | 2002-04-25 | — | — | US | claimed |
| EP-1177792-A2 | Dopamine D4 Ligands for the treatment of novelty-seeking disorders | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | claimed |
| US-20040198734-A1 | 2-(4-Aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives interacting with the dopamine | PFIZER INC | 2004-10-07 | — | — | US | disclosed |
| US-20040116443-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC | 2004-06-17 | — | — | US | disclosed |
| US-20030158208-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC. | 2003-08-21 | — | — | US | disclosed |
| US-20030100757-A1 | 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives interacting with the dopamine D4 receptor | PFIZER INC. | 2003-05-29 | — | — | US | disclosed |
| US-6548502-B2 | Preventing disorder selected from pathological gambling, attention deficit disorder with hyperactivity disorder, substance addiction such as drug and alcohol and sex in a mammals by administering pyrido(1,2-a) pyrazine derivatives | PFIZER INC | 2003-04-15 | — | — | US | disclosed |
| US-20020049209-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC. | 2002-04-25 | — | — | US | disclosed |
| EP-1177792-A2 | Dopamine D4 Ligands for the treatment of novelty-seeking disorders | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | disclosed |
| EP-1003739-A2 | 2-(4-ARYL OR HETEROARYL-PIPERAZIN-1-YLMETHYL)-1H-INDOLE DERIVATIVES | Pfizer Products Inc. (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999009025-A2 | 2-(4-ARYL OR HETEROARYL-PIPERAZIN-1-YLMETHYL)-1H-INDOLE DERIVATIVES INTERACTING WITH THE DOPAMINE D4 RECEPTOR | PFIZER PRODUCTS INC. (US) | 1999-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049209-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | SLC6A3, DRD4, DRD2 | DRD3 6/4885DRD2 3/4885HTR1A 85/4885 |
| US-20030158208-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | SLC6A3, DRD4, DRD2 | DRD3 6/4885DRD2 3/4885HTR1A 85/4885 |
| US-20030100757-A1 | 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives interacting with the dopamine D4 receptor | DRD2, DRD3, DRD4 | DRD3 2/4885DRD2 1/4885HTR1A 14/4885 |
| US-20040198734-A1 | 2-(4-Aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives interacting with the dopamine | DRD2, DRD3, TPH1 | DRD3 2/4885DRD2 1/4885HTR1A 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.